Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Archives - Page 2 of 9

Common cold antibodies hold clues to Covid-19 behavior; lung scans speed Covid-19 diagnosis in stroke patients

Adults, Children, Common cold antibodies, Computed Tomography (CT) Scans, Coronavirus Disease 2019 (COVID-19), Covid-19 Pneumonia, Emergency Rooms, Hospitalized COVID-19 Patients, Infected Cells, Lung Imaging, Medical Journals, Novel Coronavirus, Science, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Strokes

In a Reuters roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, common cold antibodies yield clues to Covid-19 behavior.

November 6, 2020/by Andrew Humphreys

Lung damage found in Covid dead may shed light on ‘long COVID’ – study

Blood Clots, Cells, COVID-19 Studies, Lancet eBioMedicine, Long COVID, Lung Damage, Lungs, Pneumonia, R&D, Reuters, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

A study of the lungs of people who have died from Covid-19 found persistent and extensive lung damage in most cases and may help doctors understand what is behind a syndrome known as ‘long Covid’, in which patients suffer ongoing symptoms for months.

November 3, 2020/by Andrew Humphreys

UK Government Plans Human Covid-19 Challenge Trials with CRO

Challenge Trials, Clinical Trials, Contract Research Organization (CRO), COVID-19 Vaccines, European Medicines Agency (EMA), FDA, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), U.K. Government

The UK government’s Covid-19 Vaccine Taskforce and the contract research company Open Orphan announced a $13 million (£10 million) plan to test investigational vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes Covid-19.

October 20, 2020/by Andrew Humphreys

Novel coronavirus can last 28 days on glass and currency, study finds

Australia, Commonwealth Scientific and Industrial Research Organization (CSIRO) (Australia), Coronavirus Disease 2019 (COVID-19), Epicenter, Fat, Government Agencies, Influenza A, Proteins, R&D, Researchers, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Studies, Virology Journal

Australian researchers said the virus that causes Covid-19 can survive on banknotes, glass and stainless steel for up to 28 days, much longer than the flu virus, highlighting the need for frequent cleaning and handwashing.

October 11, 2020/by Andrew Humphreys

Global Trial Launches to Test Remdesivir with hIVIG in Covid-19

Antivirals, Biomedical Advanced Research and Development Authority (BARDA), Business, Clinical Trials, Collaborations, Data, Immunoglobulin G (IgG), National Institutes of Health, R&D, Remdesivir, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).

October 9, 2020/by Andrew Humphreys

J&J’s Single-Dose Covid-19 Vaccine Generates Strong Immune Response, Early Data Shows

Antibodies, Clinical Trials, COVID-19 Vaccinations, COVID-19 Vaccines, Immune Response, Interim Data, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Days after Johnson & Johnson moved JNJ-78436735 into Phase III development, the company posted an interim analysis of a Phase I/IIa trial that showed a single dose of the novel coronavirus vaccine candidate induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.

September 28, 2020/by Andrew Humphreys

Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.

September 25, 2020/by Andrew Humphreys

Study: SARS-CoV-2 Infection During Pregnancy Does Not Increase Risk of Complications

Analysis, Coronavirus Disease 2019 (COVID-19), Infants, JAMA, Pregnancies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Studies, Women

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.

September 24, 2020/by Andrew Humphreys

iBio’s FastPharming Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2

ACE2 (angiotensin-converting enzyme-2), Business, Immunoadhesin Molecules, Licensing, Product Pipeline, R&D, Recombinant Proteins, SARS-CoV-2 spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Therapeutics

iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.

September 16, 2020/by Andrew Humphreys

AstraZeneca Resumes U.K. Portion of Covid-19 Vaccine Study Following Safety Review

Adenovirus, Clinical Data, Clinical Trials, COVID-19 Vaccines, Genetic material, Medicines and Healthcare products Regulatory Agency (MHRA), Oxford University, Proteins, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), T-Cells, United Kingdom, United States

AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

September 14, 2020/by Andrew Humphreys